Jacobio Pharma’s Pan-KRAS Inhibitor JAB-23E73 Clears FDA Hurdle for Clinical Trials

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has received the green light from the U.S. Food and Drug Administration (FDA) to commence a Phase I/IIa clinical study for its investigational new drug, JAB-23E73. This in-house developed pan-KRAS inhibitor has shown promise in simultaneously inhibiting both active and inactive forms of KRAS, a mutation commonly found across various tumor types, without significant inhibition of HRAS and NRAS. The drug has demonstrated favorable pharmacokinetic properties in preclinical trials and is now advancing towards human testing. The IND filing for JAB-23E73 has also been submitted in China, marking a significant step in the global development of this potential therapeutic agent.- Flcube.com